# Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.

> **NCT06183801** · NA · COMPLETED · sponsor: **Glac Biotech Co., Ltd** · enrollment: 82 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Probiotics 1
- **DIETARY_SUPPLEMENT:** Probiotics 2
- **DIETARY_SUPPLEMENT:** Probiotics 3
- **DIETARY_SUPPLEMENT:** Probiotics 4
- **DIETARY_SUPPLEMENT:** Probiotics 5
- **DIETARY_SUPPLEMENT:** Placebo 1
- **DIETARY_SUPPLEMENT:** Probiotics 6
- **DIETARY_SUPPLEMENT:** Probiotics 7
- **DIETARY_SUPPLEMENT:** Placebo 2

## Key facts

- **NCT ID:** NCT06183801
- **Lead sponsor:** Glac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-03-31
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06183801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06183801, "Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06183801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*